Novel Lyme Disease Vaccine Shows Promise In Phase 1 Trial

MedPage Today (7/10, Hein) reports, “A novel multivalent outer surface protein A (OspA)-based vaccine candidate (VLA15) against Lyme borreliosis (Lyme disease) appeared safe and generated immunogenicity in young adults, according to phase I trial results....